Pfizer is facing more disappointment with the development of some of its most advanced anticancers after Sutent (sunitinib) failed two more Phase III trials in advanced breast cancer - ending development for the drug in the disease - and figitumumab ...
Roche 's Avastin (bevacizumab), the world's best-selling cancer drug, has failed to prolong overall survival in its only Phase III trial in advanced prostate cancer, CALGB 90401, which was sponsored by the US National Cancer Institute (NCI).
Roche ...
AVEO Pharmaceuticals has finally launched its IPO, after delaying the pricing by a day.
The cancer-focused biopharmaceutical company priced 9 million shares of its common stock at $9 per share after Nasdaq closed on March 11th. However, AVEO had ...
Singapore has launched a new national cancer centre which it expects to play a key role in the advancement of novel therapies for malignancies prevalent in the Asia-Pacific region.
The National University Cancer Institute, Singapore, was formally ...
Around 300 products will escape a reduction in the next regular revision of reimbursement prices for prescription drugs in Japan on April 1st because they meet certain criteria under complex new rules being adopted on a trial basis this ...
